Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea

被引:85
|
作者
Kim, Ji Won [1 ]
Lee, Kook Lae [1 ]
Jeong, Ji Bong [1 ]
Kim, Byeong Gwan [1 ]
Shin, Sue [2 ]
Kim, Joo Sung [3 ]
Jung, Hyun Chae [3 ]
Song, In Sung [3 ]
机构
[1] Seoul Natl Univ, Coll Med, Div Gastroenterol & Hepatol, Boramae Hosp,Dept Internal Med, Seoul 156707, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Lab Med, Boramae Hosp, Seoul 156707, South Korea
[3] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Div Gastroenterol & Hepatol,Coll Med, Seoul 110744, South Korea
关键词
Clostridium difficile; Diarrhea; Recurrence; Risk factors; Proton pump inhibitors; HOSPITALIZED-PATIENTS; ANTIBODY-RESPONSE; TOXIN-A; INFECTION; DISEASE; COLITIS; ACID; EPIDEMIOLOGY; OMEPRAZOLE; THERAPY;
D O I
10.3748/wjg.v16.i28.3573
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: To investigate the risk factors for Clostridium-difficile-associated diarrhea (CDAD) recurrence, and its relationship with proton pump inhibitors (PPIs). METHODS: Retrospective data of 125 consecutive hospitalized patients diagnosed with CDAD between January 2006 and December 2007 were collected by medical chart review. Collected data included patient characteristics at baseline, underlying medical disease, antibiotic history before receiving a diagnosis of CDAD, duration of hospital stay, severity of CDAD, concurrent treatment with PPIs, laboratory parameters, response to CDAD therapy, and recurrence of disease within 90 d of successful treatment. Various clinical and laboratory parameters were compared in patients in whom CDAD did or did not recur. RESULTS: Of the 125 patients (mean age, 67.6 +/- 13.9 years) that developed CDAD, 98 (78.4%) did not experience recurrence (non-recurrent group) and 27 (21.6%) experienced one or more recurrences (recurrent group). Prior to the development of CDAD, 96% of the 125 patients were prescribed antibiotics, and 56 (44.8%) of the patients received PPIs. Age older than 65 years (P = 0.021), feeding via nasogastric tube (NGT) (P = 0.045), low serum albumin level (P = 0.025), and concurrent use of PPIs (P = 0.014) were found to be risk factors for CDAD recurrence by univariate analysis. However, sex, length of hospital stay, duration and type of antibiotics used, severity of disease, leukocyte count and C-reactive protein (CRP) were not associated with risk of CDAD recurrence. On multivariate analysis, the important risk factors were advanced age (> 65 years, adjusted OR: 1.32, 95% CI: 1.12-3.87, P = 0.031), low serum albumin level (< 2.5 g/dL, adjusted OR: 1.85, 95% CI: 1.35-4.91, P = 0.028), and concurrent use of PPIs (adjusted OR: 3.48, 95% CI: 1.64-7.69, P = 0.016). CONCLUSION: Advanced age, serum albumin level < 2.5 g/dL, and concomitant use of PPIs were found to be significant risk factors for CDAD recurrence.
引用
收藏
页码:3573 / 3577
页数:5
相关论文
共 50 条
  • [1] Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea
    Ji Won Kim
    Kook Lae Lee
    Ji Bong Jeong
    Byeong Gwan Kim
    Sue Shin
    Joo Sung Kim
    Hyun Chae Jung
    In Sung Song
    World Journal of Gastroenterology, 2010, 16 (28) : 3573 - 3577
  • [2] Clostridium difficile infection in the community: Are proton pump inhibitors to blame?
    Freedberg, Daniel E.
    Abrams, Julian A.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (40) : 6710 - 6713
  • [3] Proton pump inhibitors and risk of Clostridium difficile infection: association or causation?
    Villafuerte-Galvez, Javier A.
    Kelly, Ciaran P.
    CURRENT OPINION IN GASTROENTEROLOGY, 2018, 34 (01) : 11 - 18
  • [4] Proton-pump inhibitors and the risk of Clostridium difficile-associated diarrhea in high-risk antibiotics users: A population-based case-crossover study
    Hong, Sung-Hyun
    Lee, Eui-Kyung
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (04) : 479 - 488
  • [5] Clostridium difficile infection and proton pump inhibitors
    Pohl, John F.
    CURRENT OPINION IN PEDIATRICS, 2012, 24 (05) : 627 - 631
  • [6] Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection
    Turco, R.
    Martinelli, M.
    Miele, E.
    Roscetto, E.
    Del Pezzo, M.
    Greco, L.
    Staiano, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (07) : 754 - 759
  • [7] Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors
    Lewis, Paul O.
    Litchfield, John M.
    Tharp, Jennifer L.
    Garcia, Rebecca M.
    Pourmorteza, Mohsen
    Reddy, Chakradhar M.
    PHARMACOTHERAPY, 2016, 36 (09): : 986 - 993
  • [8] Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection
    Linsky, Amy
    Gupta, Kalpana
    Lawler, Elizabeth V.
    Fonda, Jennifer R.
    Hermos, John A.
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (09) : 772 - 778
  • [9] INTRAVENOUS TEICOPLANIN DOES NOT PREVENT CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHEA
    WENISCH, C
    ETZERSDORFER, E
    BREYER, S
    GRANINGER, W
    CLINICAL INVESTIGATOR, 1994, 72 (11): : 922 - 924
  • [10] Clostridium difficile associated diarrhea in children
    Rodriguez, Pilar
    Cofre, Jose
    REVISTA CHILENA DE INFECTOLOGIA, 2015, 32 (05): : 550 - 558